An In-situ glucose-stimulated insulin secretion assay under perfusion bioreactor conditions.

Biotechnol Prog

Laboratoire de bio-ingénierie et de biophysique de l'Université de Sherbrooke, Dept. of Chemical and Biotechnological Engineering, Université de Sherbrooke, 2500 boulevard de l'Université, Sherbrooke, QC, J1K 2R1, Canada.

Published: March 2017

Perfusion bioreactors, unlike traditional in vitro cell culture systems, offer stringent control of physiological parameters such as pH, flow, temperature, and dissolved oxygen concentration which have been shown to have an impact on cellular behaviour and viability. Due to the relative infancy and the growing interest in these in vitro culture systems, detection methods to monitor cell function under dynamic perfusion bioreactor conditions remains one of the main challenges. In this study, INS-1 cells, a cell line which exhibit glucose-stimulated insulin secretion, were embedded in fibrin and cultured under perfusion bioreactor conditions for 48 h and then exposed to either a high-, or low-glucose concentration for 24 h. These cultures were compared to non-bioreacted controls. Bioreacted cultures exposed to a high-glucose concentration showed the highest glucose-stimulated insulin secretion when compared to those in a low-glucose environment. The stimulation index, a marker for insulin secretion functionality, increased over time. A lower incidence of apoptotic cells was observed in the bioreacted cultures when compared to non-bioreacted ones, as evaluated by a TUNEL assay. Immunofluorescence staining of Ki67 and insulin was performed and showed no differences in the incidence of proliferative cells between conditions (bioreacted and non-bioreacted), where all cells stained positive for insulin. © 2016 American Institute of Chemical Engineers Biotechnol. Prog., 33:454-462, 2017.

Download full-text PDF

Source
http://dx.doi.org/10.1002/btpr.2407DOI Listing

Publication Analysis

Top Keywords

insulin secretion
16
glucose-stimulated insulin
12
perfusion bioreactor
12
bioreactor conditions
12
culture systems
8
cultures compared
8
compared non-bioreacted
8
bioreacted cultures
8
insulin
6
in-situ glucose-stimulated
4

Similar Publications

Introduction: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but can give rise to immune-related adverse events such as ICI-related diabetes mellitus (DM).

Case Presentation: We herein present the case of a 59-year-old Japanese man with malignant melanoma who developed ICI-related DM after 18 months of nivolumab treatment. He experienced marked hyperglycemia and diabetic ketoacidosis without a personal or family history of diabetes.

View Article and Find Full Text PDF

Context: Statin treatment lowers low-density lipoprotein (LDL) cholesterol thereby reducing cardiovascular risk. Meta-analyses of clinical trials report a higher risk of new-onset type 2 diabetes with statins. Current clinical evidence regarding effects of statins on insulin sensitivity and beta-cell function is limited.

View Article and Find Full Text PDF

Background: Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder in women of reproductive age. Anovulation is one of the most important clinical features of PCOS, and insulin resistance (IR) is one of the critical pathogenic factors. Woxuanzhongzhou (WXZZ) is a traditional herbal formulation that has shown efficacy in treating PCOS combined with IR, but the underlying mechanism is not clear.

View Article and Find Full Text PDF

Purpose: Our study aimed to discern disparities in metabolic, hormonal profiles, and comorbidities among patients with pituitary Cushing (PC), adrenal Cushing (AC), and Mild autonomous cortisol secretion (MACS).

Methods: We conducted a retrospective analysis involving 76 patients diagnosed with PC ( = 26), AC ( = 21), and MACS ( = 29) at our clinic. We compared the groups' demographic data, clinical characteristics, biochemical profiles, hormonal analyses, and surgical interventions.

View Article and Find Full Text PDF

Dissection of type 2 diabetes: a genetic perspective.

Lancet Diabetes Endocrinol

January 2025

Université de Lille, Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, Lille University Hospital, Lille, France; Department of Metabolism, Imperial College London, London, UK. Electronic address:

Diabetes is a leading cause of global mortality and disability, and its economic burden is substantial. This Review focuses on type 2 diabetes, which makes up 90-95% of all diabetes cases. Type 2 diabetes involves a progressive loss of insulin secretion often alongside insulin resistance and metabolic syndrome.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!